Industry

MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation

LYON, France–(BUSINESS WIRE)–$MAAT #ASH–Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced that Florent Malard, MD, PhD, hematology professor at Saint‑Antoine Hospital and Sorbonne University, presented the final results from … [Read more…]

Priority Health Appoints Brian Steele, D.O., as Chief Medical Officer

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–After a nationwide search, Priority Health, a Michigan-based, nationally recognized nonprofit health plan serving 1.4 million members, has named Brian Steele, D.O., as senior vice president and chief medical officer. He will join Priority Health on April 6, 2026. Dr. Steele will lead Priority Health’s clinical and pharmacy programs, the development and … [Read more…]

Integrated DNA Technologies Expands into Clinical Diagnostics with First In Vitro Diagnostic

Milestone marks first of multiple planned diagnostic product launches on NGS roadmap Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in vitro diagnostic BOULDER, Colo.–(BUSINESS WIRE)–#IVD–Global genomics leader Integrated DNA Technologies (IDT) today announced the launch of Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx in vitro diagnostic (IVD) offerings. This milestone … [Read more…]

Latent-Y: The Autonomous AI Agent for Drug Design at Scale

Scalable, parallel drug design: one researcher can run multiple campaigns simultaneously across targets and modalities From research goal to lab-ready sequences in hours: Latent-Y compresses weeks of expert work into autonomous design campaigns Lab-validated results across three antibody design campaigns: achieving a 67% target-level success rate with single-digit nanomolar affinities—without human filtering or intervention Powered … [Read more…]

DNP Establishes Second Overseas R&D Base in IIT Hyderabad, India

-Accelerating commercialization of wireless power supplies for EVs and active pharmaceutical ingredients with an eye on the Indian and African markets- TOKYO–(BUSINESS WIRE)–#IITH–Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) will establish a new research and development base in Telangana, India, in April 2026, to advance and reinforce its global R&D strategy. The base will be … [Read more…]

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

DUBLIN–(BUSINESS WIRE)–$PRTA #Prothena–Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases … [Read more…]

SunnyFit Celebrates 4-Year Anniversary with “Year 4 Everyone” Challenge and Community Giveaway Event

The free fitness platform marks milestone with multi-week challenge, new features, and livestream giveaway. INDUSTRY, Calif.–(BUSINESS WIRE)–SunnyFit, the free fitness app developed by Sunny Health & Fitness, is celebrating its fourth anniversary with the Year 4 Everyone Challenge & Giveaways Event, running from March 6 through March 26, 2026. The celebration highlights the platform’s growing … [Read more…]

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted … [Read more…]

Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology

SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio’s innovative microphysiological systems with Battelle’s extensive GLP-ready infrastructure to offer a transformative, … [Read more…]

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin Lymphoma (cHL) With approval in the EU, Opdivo in combination with brentuximab vedotin is now the … [Read more…]